Free Webex Call
The global venom-based drugs market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of various diseases, and rise in initiatives by government and private organizations, which are curbing the growth of the market. Venom is a compound which is secreted by an animal. It is a poisonous compound which intended to harm or disable their prey or enemy. When venom is produced through organisms, it includes variety of bioactive components which produce toxic effects. Only those active components of these venoms are isolated, purified, and screened which may have desirable therapeutic properties. The other factors supporting the market’s growth are, the extensive research and development, large number of clinical trials, increasing awareness, and government investments, large number of venomous animals, ease in approval of new venom-based drugs, and technological advancements in this field.Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Increasing Use of Venom in Numerous Diseases
Venom derived drugs are very useful in treating various diseases such as cancer, heart attack, hypertension, acute coronary syndrome, and other, due to their potential therapeutic values, which propels the growth of the market. Several venom-based drugs are already in use such as captopril, integrilin, reptilase, exanta and others. Moreover, these venom-based drugs are used as diagnostic tools, cosmeceuticals and for drug discovery. For instance, in 2020, a study concluded that bee venom therapy might be useful in treating inflammatory forms of arthritis. Similarly, captopril is a type of drug used to cure high blood pressure and reduce the risk of heart failure after a heart attack. It is derived from a species of pit viper which is found in Brazil.Technological Advancements and Rise in R&D activities
Owing to rising number of patients suffering from variety of diseases, the surge in demand for the treatment, is augmenting the growth of the market, globally. Various R&D activities are carried by researchers in order to treat these diseases using venom from various animals. The toxins from venom such as proteins, peptides, carbohydrates, and other components are important research tools. Subsequently, other reasons that make animal venoms attractive to researchers across the globe are the specialization, richness, and efficiency of the components present. Also, advancement in genomics, transcriptions and proteomics helps in study of these toxins, which further aids scientists to understand the venoms and their target. For instance, tozuleristide, a diagnostic drug obtained from the venom of the Israeli deathstalker scorpion, is now in clinical trials. An element of the venom, called chlorotoxin, binds to tumor cells. Researchers at the Fred Hutchinson Cancer Research Center re-engineered this protein and attached a fluorescent tag to it, resulting in a diagnostic tool that seeks out and illuminates tumors.Market Segmentation
The global venom-based drugs market is segmented into animal type, source, therapeutic area, and company. Based on animal type, the market is divided into snake, spider, bee, and others. Based on source, the market is divided into whole venom, synthetic, recombinant, and others. Based on therapeutic area, the market is segmented into hypertension, cardiovascular diseases, neurological disorders, pain management & arthritis, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to extensive research and development on venom based drugs in the country.Market Players
AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pentapharm Limited Medicure Inc, Millennium Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Elan Pharmaceuticals, Inc., and Beijing Tobishi Pharmaceutical Co., Ltd. are some of the leading companies operating in the market.Report Scope:
In this report, global venom based drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Venom Based Drugs Market, By Animal Type:
- Snake
- Spider
- Bee
- Others
Venom Based Drugs Market, By Source:
- Whole Venom
- Synthetic
- Recombinant
- Others
Venom Based Drugs Market, By Therapeutic Area:
- Hypertension
- Cardiovascular Diseases
- Neurological Disorders
- Pain Management & Arthritis
- Others
Venom Based Drugs Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Venom Based Drugs Market
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Venom Based Drugs Market4. Executive Summary6. List of Venom Based Approved Drugs by the FDA7. Clinical Trials Analysis15. Market Trends & Developments17. Strategic Recommendations
5. Voice of Customer
8. Global Venom Based Drugs Market Outlook
9. North America Venom Based Drugs Market Outlook
10. Europe Venom Based Drugs Market Outlook
11. Asia-Pacific Venom Based Drugs Market Outlook
12. South America Venom Based Drugs Market Outlook
13. Middle East and Africa Venom Based Drugs Market Outlook
14. Market Dynamics
16. Competitive Landscape
Companies Mentioned
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Pentapharm Limited
- Medicure Inc
- Millennium Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
- Novartis AG
- Elan Pharmaceuticals, Inc.
- Beijing Tobishi Pharmaceutical Co., Ltd.